Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 8/20 | 0.55 |
| ▸ | KIF11 | P52732 | 7/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13097626 | 0.85 | CYP2D6 (0.68) | CYP2D6KIF11ALDH1A1LMNAMAPT | |
| SCHEMBL13097624 | 0.85 | CYP2D6 (0.64) | CYP2D6KIF11ALDH1A1LMNAMAPT | |
| SCHEMBL3098321 | 0.84 | CYP2D6 (0.58) | CYP2D6KIF11ALDH1A1LMNAMAPT | |
| SCHEMBL3094907 | 0.80 | CYP2D6 (0.60) | CYP2D6KIF11ALDH1A1LMNAMAPT | |
| SCHEMBL13097841 | 0.79 | CYP2D6 (0.57) | CYP2D6LMNAMAPT | |
| SCHEMBL13097807 | 0.78 | CYP2D6 (0.60) | CYP2D6KIF11LMNAMAPT | |
| SCHEMBL13097690 | 0.78 | CYP2D6 (0.59) | CYP2D6ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL13097784 | 0.77 | CYP2D6 (0.60) | CYP2D6ALDH1A1LMNAKMT2A | |
| SCHEMBL13097520 | 0.77 | CYP2D6 (0.59) | CYP2D6KIF11ALDH1A1MAPTKMT2A | |
| SCHEMBL3094832 | 0.76 | CYP2D6 (0.61) | CYP2D6KIF11LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2194044-A1 | QUINOLONE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256113-A1 | QUINOLONE DERIVATIVE | NQO1, NQO2, NADK | CYP2D6 230/4885KIF11 4708/4885SLC6A2 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.